FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to clinical and laboratory diagnostics. Determining the absolute number of eosinophils, the number of erythrocytes, the concentration of C-reactive protein in the blood, the absolute number of neutrophils, ESR, blood haemoglobin concentration, blood ferritin concentration, arterial oxygen saturation level, blood LDH concentration, blood D-dimer concentration, absolute lymphocyte count. Original formula is used to determine the severity of the infection caused by SARS-CoV-2 in young people (P). If P is less than 0.5, a mild course of the infection caused by SARS-CoV-2 is predicted, and if P is greater than or equal to 0.5, a severe course of the infection caused by SARS-CoV-2 is predicted.
EFFECT: method enables to predict the severity of the infection caused by SARS-CoV-2 in young people in the initial period of the disease, which in turn makes it possible to provide the necessary medical assistance to patients in a timely manner.
1 cl, 2 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR ASSESSING UNFAVORABLE OUTCOME OF SEVERE PNEUMONIA ASSOCIATED WITH COVID-19 BY s-CysC LEVEL | 2022 |
|
RU2779581C2 |
METHOD FOR ASSESSING UNFAVORABLE OUTCOME OF SEVERE PNEUMONIA ASSOCIATED WITH COVID-19 BY u-CysC LEVEL | 2022 |
|
RU2779579C2 |
BROADLY NEUTRALIZING ANTIBODY AGAINST SARS-CoV-2 | 2022 |
|
RU2810476C1 |
METHOD FOR DETERMINING THE FUNCTIONAL ACTIVITY OF THE HUMAN COMPLEMENT SYSTEM FOR PREDICTING THE SEVERITY OF THE COURSE OF A SYSTEMIC INFLAMMATORY REACTION | 2021 |
|
RU2756764C1 |
LIPOSOMAL COMPOSITION OF 5-CHLOROPYRIDIN-3-IL-1H-INDOL-4-CARBOXYLATE AS A POTENTIAL EMERGENCY PREVENTION AND TREATMENT OF CORONAVIRUS INFECTIONS | 2023 |
|
RU2810261C1 |
METHOD FOR PREDICTING THE OCCURRENCE OF ACUTE KIDNEY INJURY IN COVID-19-ASSOCIATED PNEUMONIA BASED ON THE LEVEL OF s-CysC | 2022 |
|
RU2788298C2 |
METHOD OF PREDICTING COMPLICATIONS AFTER COVID-19 IN PERSONS WITH COMORBID BACKGROUND IN THE ARCTIC REGION | 2023 |
|
RU2812780C1 |
METHOD FOR PREDICTING THE RISK OF DEVELOPING COVID-19 IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES | 2022 |
|
RU2783422C1 |
APPLICATION OF N,N'-BIS-(2,3-BUTADIENYL)-1,4-DIAMINOBUTANE DIHYDROCHLORIDE (MDL72.527) FOR SUPPRESSING REPLICATION OF SARS-COV-2 VIRUS | 2020 |
|
RU2761565C1 |
METHOD FOR EARLY DETECTION OF NEUROLOGICAL DISORDERS IN PATIENTS WITH COVID-19 | 2021 |
|
RU2779562C1 |
Authors
Dates
2024-06-25—Published
2024-01-23—Filed